Anti-CD44 antibodies inhibit both mTORC1 and mTORC2: a new rationale supporting CD44-induced AML differentiation therapy

Samah Gadhoum, Nour Yaseen Rabah Madhoun, Ayman AbuElela, Jasmeen Merzaban

Research output: Contribution to journalArticlepeer-review

15 Scopus citations
Original languageEnglish (US)
Pages (from-to)2397-2401
Number of pages5
JournalLeukemia
Volume30
Issue number12
DOIs
StatePublished - Aug 8 2016

Cite this